Cargando…

Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer

Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type colorectal cancers (CRC) but acquired resistance invariably evolves. Which mutational mechanisms enable resistance evolution and whether adaptive mutagenesis, a transient cetuximab-induced increase in mutation generation,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woolston, Andrew, Barber, Louise J, Griffiths, Beatrice, Pich, Oriol, Lopez-Bigas, Nuria, Matthews, Nik, Rao, Sheela, Watkins, David, Chau, Ian, Starling, Naureen, Cunningham, David, Gerlinger, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7611134/ https://www.ncbi.nlm.nih.gov/pubmed/34017094 http://dx.doi.org/10.1038/s41559-021-01470-8

Ejemplares similares

Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2019)

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment
por: Newey, Alice, et al.
Publicado: (2019)

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
por: Gonzalez-Exposito, Reyes, et al.
Publicado: (2019)

Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data
por: Khan, Khurum, et al.
Publicado: (2020)

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
por: Woolston, Andrew, et al.
Publicado: (2019)

Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey
por: Moorcraft, Sing Yu, et al.
Publicado: (2016)

Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study
por: Moussa, Osama, et al.
Publicado: (2022)

Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer
por: von Loga, Katharina, et al.
Publicado: (2020)

Author Correction: Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer
por: von Loga, Katharina, et al.
Publicado: (2020)

Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk
por: Fotiadis, Nicos, et al.
Publicado: (2020)

Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience
por: Khan, Khurum, et al.
Publicado: (2015)

Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes
por: Challoner, Benjamin R, et al.
Publicado: (2020)

Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study
por: Moorcraft, Sing Yu, et al.
Publicado: (2016)

Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma
por: Abbas, Sujath, et al.
Publicado: (2023)

The evolution of hematopoietic cells under cancer therapy
por: Pich, Oriol, et al.
Publicado: (2021)

The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing
por: Chong, Irene Y., et al.
Publicado: (2021)

Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy
por: Knebel, Franciele H., et al.
Publicado: (2020)

Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center
por: Georgiou, Alexandros, et al.
Publicado: (2019)

Discovering the drivers of clonal hematopoiesis
por: Pich, Oriol, et al.
Publicado: (2022)

Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies
por: Butters, Oliver, et al.
Publicado: (2019)

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial
por: Khan, Khurum, et al.
Publicado: (2016)

Role of erlotinib in the management of pancreatic cancer
por: Starling, Naureen, et al.
Publicado: (2006)

The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy
por: Andreyev, H. Jervoise N., et al.
Publicado: (2020)

The mutational footprints of cancer therapies
por: Pich, Oriol, et al.
Publicado: (2019)

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
por: Lau, David K., et al.
Publicado: (2023)

The evolving immunotherapeutic landscape in advanced oesophagogastric cancer
por: Flynn, Michael, et al.
Publicado: (2018)

Contemporary Tailored Oncology Treatment of Biliary Tract Cancers
por: Turkes, Fiona, et al.
Publicado: (2019)

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study
por: Turkes, Fiona, et al.
Publicado: (2022)

Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
por: Barber, Louise J, et al.
Publicado: (2015)

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers
por: Smyth, Elizabeth C, et al.
Publicado: (2021)

Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer
por: Davidson, Michael, et al.
Publicado: (2017)

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
por: Lau, David, et al.
Publicado: (2020)

Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
por: Young, Kate, et al.
Publicado: (2018)

Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma
por: Fong, Caroline Y. K., et al.
Publicado: (2019)

Genomic loss of heterozygosity and survival in the REAL3 trial
por: Smyth, Elizabeth C., et al.
Publicado: (2018)

An Intronic microRNA Links Rb/E2F and EGFR Signaling
por: Truscott, Mary, et al.
Publicado: (2014)

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
por: Sultana, Asma, et al.
Publicado: (2008)

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine
por: Lipinski, Kamil A., et al.
Publicado: (2016)

Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials
por: Athauda, Avani, et al.
Publicado: (2023)

Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment
por: Moorcraft, Sing Y., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2k4fqrop8u7fip1agv0huuirm6